A recent phase III trial demonstrated that initial therapy with an immuno-agent improves PFS in patients with HR+, HER2- breast cancer. READ MORE

Conferences

Investigators reported results from a clinical trial comparing accelerated partial breast irradiation with whole breast irradiation.

READ MORE

Researchers from Denmark followed a group of women diagnosed with breast cancer to compare breast conserving therapy with mastectomy. 

READ MORE

Investigators examined potential biomarkers for the breast cancer gene GATA3 to see if any could be associated with patients’ survival.

READ MORE

Researchers evaluated bone health surveillance patterns, bone density outcomes, and fracture risk after salpingo-oophorectomy.

READ MORE

News

Patients with breast cancer who take opioids to manage their pain are less likely to adhere to adjuvant therapy, resulting in a higher risk of death.

READ MORE

By Megan Brooks

NEW YORK (Reuters Health) - Omitting radiation after lumpectomy for pure ductal carcinoma in situ (DCIS) does not improve the chance of breast preservation in case of local recurrence, researchers from Canada have observed.

READ MORE

A recent comparative effectiveness study examined long-term survival outcomes for patients with breast cancer after undergoing either mastectomy or breast-conserving surgery.

READ MORE

Research in Review

In younger women with hormone receptor-positive breast cancer, ovarian function suppression after surgery drives large improvements in breast cancer-free interval when combined with drug therapy.

READ MORE

Patients with human epidermal growth factor 2 (HER2)-positive breast cancer who undergo induction chemotherapy are likely to convert to HER2-negative disease if residual disease occurs, prompting further systemic therapy.

READ MORE

Patients with human epidermal growth factor receptor 2-positive breast cancer benefit from an estimated 7 additional months of survival if treated with trastuzumab emtansine rather than the physician’s choice of therapy.

READ MORE

A radiation schedule half the standard course is as safe and effective for patients with breast cancer following a mastectomy.

READ MORE